Cargando…

The safety of long-acting β(2)-agonists in the treatment of stable chronic obstructive pulmonary disease

BACKGROUND: Inhaled long-acting bronchodilators are the mainstay of pharmacotherapy for chronic obstructive pulmonary disease (COPD). Both the twice-daily long-acting β(2)-adrenoceptor agonists (LABAs) salmeterol and formoterol and the once-daily LABA indacaterol are indicated for use in COPD. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Decramer, Marc L, Hanania, Nicola A, Lötvall, Jan O, Yawn, Barbara P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558319/ https://www.ncbi.nlm.nih.gov/pubmed/23378756 http://dx.doi.org/10.2147/COPD.S39018

Ejemplares similares

Long-acting β(2)-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety
por: Rossi, Andrea, et al.
Publicado: (2008)

Ultra Long-Acting β-Agonists in Chronic Obstructive Pulmonary Disease
por: Burkes, Robert M, et al.
Publicado: (2020)

The role of combination therapy with corticosteroids and long-acting β(2)-agonists in the prevention of exacerbations in COPD
por: Cazzola, Mario, et al.
Publicado: (2006)

Long acting β(2 )agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trials
por: Husereau, Don, et al.
Publicado: (2004)

Efficacy and safety of the long-acting β(2)-agonist olodaterol over 4 weeks in Japanese patients with chronic obstructive pulmonary disease
por: Ichinose, Masakazu, et al.
Publicado: (2015)

Chronic obstructive pulmonary disease
por: Decramer, Marc, et al.
Publicado: (2012)

Inhaled steroid/long-acting β2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients
por: Lötvall, Jan, et al.
Publicado: (2006)

The efficacy and safety of additional treatment with short-acting muscarinic antagonist combined with long-acting beta-2 agonist in stable patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis
por: Tanimura, Kazuya, et al.
Publicado: (2023)

Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids
por: Liao, Pei-An, et al.
Publicado: (2023)

Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents
por: Tashkin, Donald P, et al.
Publicado: (2010)

Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis
por: Donohue, James F, et al.
Publicado: (2017)

Addressing the Use of the CAPTURE (a Chronic Obstructive Pulmonary Disease Screening Tool) in Chronic Obstructive Pulmonary Disease Treatment Decisions
por: Yawn, Barbara P., et al.
Publicado: (2023)

The role of long-acting muscarinic antagonist/long-acting β agonist fixed-dose combination treatment for chronic obstructive pulmonary disease in China: a narrative review
por: Zhou, Ji’an, et al.
Publicado: (2021)

A randomized controlled trial of long-acting muscarinic antagonist and long-acting β2 agonist fixed-dose combinations in patients with chronic obstructive pulmonary disease
por: Muraki, Masato, et al.
Publicado: (2021)

The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease
por: Kliber, Agnes, et al.
Publicado: (2010)

Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis
por: DiSantostefano, Rachael L, et al.
Publicado: (2014)

Vitamin D and Chronic Obstructive Pulmonary Disease
por: Janssens, Wim, et al.
Publicado: (2012)

The long-acting β(2)-adrenoceptor agonist olodaterol attenuates pulmonary inflammation
por: Wex, Eva, et al.
Publicado: (2015)

The responsiveness of the Manchester Chronic Obstructive Pulmonary Disease Fatigue Scale to pulmonary rehabilitation
por: Yohannes, Abebaw Mengistu, et al.
Publicado: (2019)

Management of Asthma and Chronic Obstructive Pulmonary Disease with Combination Inhaled Corticosteroids and Long-Acting β-Agonists: A Review of Comparative Effectiveness Research
por: Mapel, Douglas W., et al.
Publicado: (2014)

Therapeutic preferences and factors determining the use of inhaled corticosteroids with long-acting β(2)-agonists in patients with asthma and chronic obstructive pulmonary disease
por: Olszanecka-Glinianowicz, Magdalena, et al.
Publicado: (2020)

Effects of Roflumilast on Patients with Chronic Obstructive Pulmonary Disease Treated with Inhaled Corticosteroid/Long-Acting β2 Agonist: A Meta-analysis
por: Zeng, Shasha, et al.
Publicado: (2022)

The Saudi guidelines for chronic obstructive pulmonary disease: A fresh “Real-World” approach to COPD
por: Hanania, Nicola A.
Publicado: (2014)

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
por: Roskell, Neil S, et al.
Publicado: (2014)

Effect of Adding Inhaled Corticosteroid to Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist Therapy Among Patients With Chronic Obstructive Pulmonary Disease
por: Yuasa, Mizuki, et al.
Publicado: (2021)

Role of Tiotropium in Reducing Exacerbations of Chronic Obstructive Pulmonary Disease When Combined With Long‐Acting β (2)‐Agonists and Inhaled Corticosteroids: The OUTPUL Study
por: Ferroni, Eliana, et al.
Publicado: (2016)

Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review
por: Ridolo, Erminia, et al.
Publicado: (2013)

Characterization of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting Muscarinic Antagonist/Long-Acting β(2)-Agonist Dual Therapy in a Primary Care Setting in England
por: Requena, Gema, et al.
Publicado: (2022)

Efficacy and safety of conventional long acting β2- agonists: systematic review and meta-analysis
por: Karbasi-Afshar, Reza, et al.
Publicado: (2016)

Long acting β(2)-adrenocepter agonists are not associated with atrial arrhythmias after pulmonary resection
por: Yamanashi, Keiji, et al.
Publicado: (2017)

Optimal Bronchodilation for COPD Patients: Are All Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
por: Miravitlles, Marc, et al.
Publicado: (2018)

Management of patients during and after exacerbations of chronic obstructive pulmonary disease: the role of primary care physicians
por: Yawn, Barbara P, et al.
Publicado: (2011)

Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease
por: Celli, Bartolome R, et al.
Publicado: (2012)

A cross-sectional study of the identification of prevalent asthma and chronic obstructive pulmonary disease among initiators of long-acting β-agonists in health insurance claims data
por: Dore, David D, et al.
Publicado: (2014)

Effect of Inhaled β(2)-Agonist on Exhaled Nitric Oxide in Chronic Obstructive Pulmonary Disease
por: Amer, Mostafa, et al.
Publicado: (2016)

Assessment of the safety of long-acting β(2)-agonists in routine asthma care: the ASTRO-LAB protocol
por: Van Ganse, Eric, et al.
Publicado: (2015)

Treatment Patterns, Healthcare Utilization and Clinical Outcomes of Patients with Chronic Obstructive Pulmonary Disease Initiating Single-Inhaler Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonist Dual Therapy in Primary Care in England
por: Requena, Gema, et al.
Publicado: (2023)

GOLD in Practice: Chronic Obstructive Pulmonary Disease Treatment and Management in the Primary Care Setting
por: Yawn, Barbara P, et al.
Publicado: (2021)

Practical aspects of inhaler use in the management of chronic obstructive pulmonary disease in the primary care setting
por: Yawn, Barbara P, et al.
Publicado: (2012)

Activity-related dyspnea in chronic obstructive pulmonary disease: physical and psychological consequences, unmet needs, and future directions
por: Hanania, Nicola A, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_op2e935m9d98dstha3nnjr1lk0